SRF-114 is under clinical development by Surface Oncology and currently in Phase II for Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Head And Neck Cancer Squamous Cell Carcinoma have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SRF-114’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SRF-114 overview

SRF-114 is under development for the treatment of solid tumor and head and neck squamous cell carcinoma. The drug candidate is a afucosylated IgG1 antibody acts by targeting chemokine receptor CCR8. It is developed based on ActivMAb antibody discovery platform.

Surface Oncology overview

Surface Oncology is an immuno-oncology company. It develops novel antibody therapies for the treatment of cancer. The company’s product portfolio includes SRF388, to treat various diseases like renal cell carcinoma, hepatocellular carcinoma, and non-small-cell lung cancer; SRF617, to treat various tumors like gastric cancer, prostate cancer, PD-(L)1 relapsed cancer, and pancreatic cancer. Surface Oncology also provides SRF114, NZV930 and GSK4381562 antibodies. It also carries out research and development activities and pre-clinical studies. The company has entered two strategic collaborations to advance our next-generation cancer therapies partners which include Novartis and GSK. Surface Oncology is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of SRF-114’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.